Showing results (1431-1440 of 1,518) with videos related to
Sort By:
Pageof 152
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2021
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC TrialCorinne Faivre-Finn, David Vicente, Takayasu Kurata, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 9, 2021
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or BrainNaoyuki Nogami, Fabrice Barlesi, Mark A Socinski, et al.Lancet (London, England)|July 9, 2023
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled studySiow Ming Lee, Christian Schulz, Kumar Prabhash, et al.Lung Cancer (Amsterdam, Netherlands)|June 12, 2022
Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) surveySara Pilotto, Alice Avancini, Jessica Menis, et al.Journal for Immunotherapy of Cancer|February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trialDavid P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.Cell Metabolism|June 3, 2026
IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibitionSiavash Mansouri, Golnaz Hesami, Anoop Ambikan, et al.Antimicrobial Agents and Chemotherapy|August 1, 2018
Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing <i>In Vitro</i> Susceptibility in Escherichia coli and Klebsiella pneumoniaeCharles R Dean, David T Barkan, Alun Bermingham, et al.ESMO Open|May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LAD P Carbone, T-E Ciuleanu, M Cobo, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysisH Borghaei, T-E Ciuleanu, J-S Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451Taofeek K Owonikoko, Keunchil Park, Ramaswamy Govindan, et al.Pageof 152